Cross-clade neutralizing antibody production against human immunodeficiency virus type 1 clade E and B′ strains by recombinant Mycobacterium bovis BCG-based candidate vaccine

Vaccine

Volumn 20, Issue 5-6, 2001, Pages 797-804

  Chujoh, Yoshitomo ^a   Matsuo, Kazuhiro ^a,c   Yoshizaki, Hitomi ^b   Nakasatomi, Tetsuya ^b   Someya, Kenji ^b   Okamoto, Yukari ^b   Naganawa, Satoshi ^b   Haga, Shinji ^b   Yoshikura, Hiroshi ^b   Yamazaki, Akihiro ^a   Yamazaki, Shudo ^b   Honda, Mitsuo ^b,c  

^a AJINOMOTO CO INC   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

HIV; HIV vaccine; Mycobacterium bovis BCG; Neutralization antibody; RBCG

Indexed keywords

BCG THA11 VACCINE; BCG THA12 VACCINE; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; EXPRESSION VECTOR; GUINEA PIG; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; MYCOBACTERIUM BOVIS; NONHUMAN; PRIORITY JOURNAL; THAILAND; VIRUS NEUTRALIZATION; VIRUS STRAIN;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; BCG VACCINE; EPITOPES; GENETIC VECTORS; GUINEA PIGS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MYCOBACTERIUM BOVIS; NEUTRALIZATION TESTS; PEPTIDE FRAGMENTS; THAILAND; VACCINES, SYNTHETIC;

EID: 0035852267     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00398-X     Document Type: Article

References (40)

1. Independent introduction of two major HIV-1 genotypes into distinct high-risk populations in Thailand
2. A characteristic change of consensus core motif in the V3 region of HIV type 1 clade B, but not in clade E, in Thailand
3. Failure of a human immunodeficiency virus type 1 (HIV-1) subtype B-derived vaccine to prevent infection of chimpanzees by an HIV-1 subtype E strain
4. Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand
5. AIDSVAX (MN) in Bangkok injecting drug users: A report on safety and immunogenicity, including macrophage-tropic virus neutralization
6. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines
7. Cytotoxic T lymphocyte response in mice induced by a recombinant BCG vaccination which produces an extracellular α-antigen that fused with the human immunodeficiency virus type 1 envelope immunodominant domain in the V3 loop
8. Oral immunization with recombinant Mycobacterium bovis BCG simian immunodeficiency virus nef induces local and systemic cytotoxic T-lymphocyte responses in mice
9. New use of BCG for recombinant vaccines
10. A vaccine elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous cell-free simian immunodeficiency virus challenge
11. Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guerin vector candidate vaccine for human immunodeficiency virus type 1 in small animals
12. Cloning and expression of the gene for cross-reactive α-antigen of Mycobacterium kansasii
13. Establishment of a foreign antigen secretion system in mycobacteria
14. Specificity and distribution of alpha antigens of Mycobacterium kansasii and Mycobacterium marinum
15. Antigenic variation and serotyping of HIV type 1 from four world health organization-sponsored HIV vaccine sites
16. A highly pathogenic simian/human immunodeficiency virus with genetic changes in cynomolgus monkey
17. In SCID-hu mice, passive transfer of a humanized antibody prevents infection and atrophic change of medulla in human thymic implant due to intravenous inoculation of primary HIV-1 isolate
18. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1
19. Immunoglobulin G (IgG) and IgA, but also non-antibody factors, account for in vitro neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by serum and plasma of HIV-infected patients
20. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120
21. A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B
22. Improved humoral and cellular immune responses against the gp120 V3 loop of HIV-1 following genetic immunization with a chimeric DNA vaccine encoding the V3 inserted into the hepatitis B surface antigen
23. Characterization of V3 loop-Pseudomonas exotoxin chimeras. Candidate vaccines for human immunodeficiency virus 1
24. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
25. Vaccine elicited V3 loop-specific antibodies in rhesus monkeys and control of simian-human immunodeficiency virus expressing a primary patients human immunodeficiency virus type 1 isolate envelope
26. Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: A new strategy for studying the immunologic relatedness of HIV-1
27. Immunotyping of human immunodeficiency virus type 1 (HIV): An aprroach to immunologic classification of HIV
28. Antibody binding and neutralization of primary and T cell line-adapted isolates of human immunodeficiency virus type 1
29. Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: Neutralization of non-pathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains
30. Elicitation of protective immunity against simian immunodeficiency virus by a recombinant Sendai virus expressing the Gag protein
31. Quintuple deglycosylation mutant of simian immunodeficiency virus SIVmac239 in Rhesus macaques: Robust primary replication, tightly contained chronic infection, and elicitation of potent immunity against the parental wild-type strain
32. Enhanced T cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus
33. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
34. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
35. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV
36. HIV-1 Langerhans' cell tropism associated with heterosexual transmission of HIV
37. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5
38. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates
39. CCR5 coreceptor usage of non-syncytium-inducing primary HIV-1 is independent of phylogenetically distinct global HIV-1 isolates: Delineation of consensus motif in the V3 domain that predicts CCR-5 usage
40. Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi